CHU Strasbourg
Strasbourg, Grand Est, 67000, France
NCT Number: NCT03912051
Between 10 and 12% of the general population suffers from epistaxis, out of which 10% would need to be medically managed. Most of patients treated for epistaxis are managed through emergency departments. The involvement of the ENT (ear, nose and throat) surgeon might be required in more complex situations in order to control bleeding.
Usually, nasal packing packing is used as a first line option after failure of digital compression. Epistaxis balloons are often used after failure of nasal packing Balloons are effective in approximately 60% of the patients with a rapid control of bleeding by compression followed by an absence of rebreeding after balloon removal.
The main challenges for patients treated with this device are i) pain upon balloon introduction and inflation ii) discomfort upon introduction in the nasal cavity as well as during balloon maintenance during 24 to 72 hours of tamponade iii) blood retention between distal and proximal balloons that favors infection iv) limited breathing capabilities through the nostrils which increases general discomfort v) negative aesthetic impact for the patient vi) septal and alar necrosis risk in case of prolonged compression.
Moreover, epistaxis leading to an hospitalization between 24 to 48h are not rare (>11 000 in France in 2017 according to ATIH). Those hospitalizations are often decided in order to ensure an optimal patient monitoring following packing or epistaxis balloon placement.
In order to address those adverse events while keeping the same efficacy and avoiding hospitalizations or reducing their duration, the use of an asymmetric, more physiological, easy to use and mainly intranasal (discreet proximal extremity) is studied.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Strasbourg, Grand Est, 67000, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Asymmetric balloon for treatment of intranasal bleeding
Other names: epistaxis balloon
Time frame: 12 days
Absence of bleeding following balloon inflation during first 48 hours and absence of rebreeding following removal at 48 hours and 9 days following removal
Time frame: 12 days
Pain score on a VAS (Visual Analogic Scale)
Time frame: 12 days
RhinoQoL (Rhino Quality of Life) score
Dianosic
Industry
Acronym: BATSI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05269849
Cardiovascular Abnormalities, Cardiovascular Diseases
Toronto, Ontario, Canada
View Trial DetailsNCT06985108
Epistaxis, Hemorrhage
Diyarbakır, Turkey (Türkiye)
View Trial DetailsNCT06906861
Epistaxis, Hemorrhage
Kathmandu, Bagmati, Nepal
View Trial DetailsNCT02517294
Epistaxis, Hemorrhage
Jacksonville, Florida, United States
View Trial Details